Further rationale for optimal combined modality treatments

Oncotarget. 2017 Apr 18;8(16):25831-25832. doi: 10.18632/oncotarget.16117.

Authors

Robert J Griffin¹, Ruud P M Dings¹, Issam Makhoul²

Affiliations

¹ Department of Radiation Oncology, Radiation Biology Division, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Department of Internal Medicine, Hematology/Oncology Division, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

No abstract available

Keywords: anti-angiogenic agent; radiotherapy; re-oxygenation; sunitinib.

Publication types

News
Comment

MeSH terms

Combined Modality Therapy
Humans
Neoplasms*